Get the Stockscreener App
4.88
3.37%
-0.17
Sophia Genetics Sa stock is traded at $4.88, with a volume of 100.71K.
It is down -3.37% in the last 24 hours and down -4.87% over the past month.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
See More
Previous Close:
$5.05
Open:
$5.12
24h Volume:
100.71K
Relative Volume:
0.99
Market Cap:
$350.34M
Revenue:
$81.18M
Net Income/Loss:
$-80.94M
P/E Ratio:
-4.1324
EPS:
-1.1809
Net Cash Flow:
$-55.15M
1W Performance:
+5.40%
1M Performance:
-4.87%
6M Performance:
+7.49%
1Y Performance:
+68.86%
1-Day Range:
$4.76
$5.20
1-Week Range:
$4.442
$5.20
52-Week Range:
$2.59
$5.70
Sophia Genetics Sa Stock (SOPH) Company Profile
Name
Sophia Genetics Sa
Sector
Industry
Phone
-
Address
-
Compare SOPH vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SOPH
Sophia Genetics Sa
|
4.88 | 362.54M | 81.18M | -80.94M | -55.15M | -1.1809 |
VEEV
Veeva Systems Inc
|
160.17 | 25.83B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
58.50 | 11.25B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.18 | 8.35B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
88.11 | 7.25B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
55.25 | 4.27B | 646.34M | -512.40M | 202.76M | -6.6871 |
Sophia Genetics Sa Stock (SOPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Craig Hallum | Buy |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-03-23 | Initiated | BTIG Research | Buy |
| Nov-23-22 | Initiated | Credit Suisse | Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-17-21 | Initiated | Cowen | Outperform |
| Aug-17-21 | Initiated | Credit Suisse | Outperform |
| Aug-17-21 | Initiated | JP Morgan | Overweight |
| Aug-17-21 | Initiated | Morgan Stanley | Overweight |
View All
Sophia Genetics Sa Stock (SOPH) Latest News
Undervalued Opportunities: Top Penny Stocks To Watch In May 2026 - Sahm
SOPHiA GENETICS (SOPH) president’s 761-share tax sale under 10b5-1 plan - Stock Titan
SOPHiA GENETICS (SOPH) CSO sells shares to cover RSU tax via 10b5-1 plan - Stock Titan
[Form 4] SOPHiA GENETICS SA Insider Trading Activity - Stock Titan
SOPHiA GENETICS (SOPH) CMO pre-planned sale of 608 shares for tax - Stock Titan
Tax-driven sale: SOPHiA GENETICS (SOPH) CLO disposes 684 shares - Stock Titan
SOPHiA GENETICS (SOPH) CPO sells 380 shares to cover RSU taxes - Stock Titan
SOPHiA GENETICS (SOPH) CSO sells 33 shares in tax sell-to-cover - Stock Titan
JURGI CAMBLONG sells shares under 10b5-1 (SOPH) - Stock Titan
Manuela Valente files Form 144 to sell SOPH shares (NASDAQ: SOPH) - Stock Titan
SOPH (NASDAQ) insider RSUs recorded; Philippe Menu reports multiple 10b5-1 sales - Stock Titan
761 RSUs filed; prior 10b5-1 sales by Ross J Muken (SOPH) - Stock Titan
Form 144: 684 RSUs flagged for sale by Morgan Stanley Smith Barney (SOPH) - Stock Titan
Rule 144: Officer/holder lists 4,608 RSUs for sale (SOPH) - Stock Titan
SOPHiA GENETICS Files Form 6-K and Publishes 2025 ESG Impact Summary - TipRanks
SOPHiA GENETICS (SOPH) publishes 2025 ESG Impact Summary for investors - Stock Titan
SOPHiA GENETICS (SOPH) CSO executes 4,000-share sale under 10b5-1 plan - Stock Titan
Insider Sell: Philippe Menu Sells 5,000 Shares of Sophia Genetics SA - GuruFocus
Director Kathy Hibbs sells SOPHiA GENETICS (SOPH) shares under 10b5-1 plan - Stock Titan
SOPHiA GENETICS (SOPH) CMO pre-planned sale of 5,000 shares - Stock Titan
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. - marketscreener.com
New NHS blood test aims to speed lung and breast cancer treatment - Stock Titan
SOPHiA Genetics inks two deals to advance AI for precision medicine - MSN
SOPHiA GENETICS (SOPH) CEO 10b5-1 sale of 8,500 shares - Stock Titan
TradingKey - tradingkey.com
How SOPHiA (SOPH) performance reflects its true potential (-4.63%) 2026-05-08Macro Trends - Newser
SOPHiA GENETICS schedules annual general meeting for June 18 in Switzerland - Investing.com Nigeria
SOPHiA GENETICS schedules annual general meeting for June 18 in Switzerland By Investing.com - Investing.com South Africa
SOPHiA GENETICS Calls 2026 AGM as It Highlights Breakout 2025 Growth - TipRanks
Leadership change and pay votes at SOPHiA GENETICS (Nasdaq: SOPH) - Stock Titan
SOPHiA GENETICS SA 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SOPH) 2026-05-07 - Seeking Alpha
SOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG Research - MarketBeat
SOPHiA GENETICS S.A. (NASDAQ:SOPH) Q1 2026 Earnings Call Transcript - Insider Monkey
BTIG reiterates Sophia Genetics stock rating on strong Q1 growth - Investing.com UK
BTIG reiterates Sophia Genetics stock rating on strong Q1 growth By Investing.com - Investing.com Australia
SOPHiA GENETICS Earnings Call: Growth With Caveats - TipRanks
SOPHiA GENETICS S.A. Q1 2026 Earnings Call Summary - Yahoo Finance
SOPHiA GENETICS Q1 Earnings Call Highlights - MarketBeat
SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript - AOL.com
SOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
SOPH: Q1 revenue up 22%, record platform usage, and strong margin; 2026 guidance reaffirmed - TradingView
SOPHiA GENETICS SA reports results for the quarter ended March 31Earnings Summary - TradingView
BTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8 - Insider Monkey
SOPHiA GENETICS Posts Higher Q1 2026 Revenue but Wider Loss in Newly Filed Form 6-K - TipRanks
SOPH: Q1 2026 revenue up 22% year-over-year, with improved margins and strong global expansion - TradingView
SOPHiA GENETICS Reports First Quarter 2026 Results - ChartMill
SOPHiA GENETICS (SOPH) grows Q1 2026 revenue 22% but remains loss-making - Stock Titan
How SOPHiA (SOPH) responds to market challenges (Technical Weakness) 2026-05-05Pre-Earnings Momentum - Newser
SOPHiA GENETICS SA expected to post a loss of 23 cents a shareEarnings Preview - TradingView
SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in Stock - MarketBeat
SOPHiA GENETICS (SOPH) CMO sells 5,000 shares under 10b5-1 plan - Stock Titan
Sophia Genetics Sa Stock (SOPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
4.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):